Parnax Lab 과거 수익 실적
과거 기준 확인 2/6
Parnax Lab has been growing earnings at an average annual rate of 55%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 17.8% per year. Parnax Lab's return on equity is 14.3%, and it has net margins of 5.4%.
주요 정보
55.0%
수익 성장률
51.0%
EPS 성장률
| Pharmaceuticals 산업 성장 | 17.5% |
| 매출 성장률 | 17.8% |
| 자기자본 수익률 | 14.3% |
| 순이익 | 5.4% |
| 최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
Parnax Lab 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 1,901 | 103 | 245 | 0 |
| 31 Mar 24 | 1,888 | 96 | 245 | 0 |
| 31 Dec 23 | 1,832 | 88 | 235 | 0 |
| 30 Sep 23 | 1,791 | 98 | 229 | 0 |
| 30 Jun 23 | 1,796 | 100 | 211 | 0 |
| 31 Mar 23 | 1,676 | 86 | 211 | 0 |
| 31 Dec 22 | 1,746 | 70 | 203 | 0 |
| 30 Sep 22 | 1,785 | 84 | 201 | 0 |
| 30 Jun 22 | 1,711 | 92 | 183 | 0 |
| 31 Mar 22 | 1,630 | 82 | 186 | 0 |
| 31 Dec 21 | 1,362 | 53 | 179 | 0 |
| 30 Sep 21 | 1,104 | 9 | 167 | 0 |
| 30 Jun 21 | 1,008 | 4 | 148 | 0 |
| 31 Mar 21 | 901 | -4 | 147 | 0 |
| 31 Dec 20 | 928 | 2 | 147 | 0 |
| 30 Sep 20 | 934 | -8 | 147 | 0 |
| 30 Jun 20 | 923 | -28 | 147 | 0 |
| 31 Mar 20 | 955 | -29 | 156 | 0 |
| 31 Dec 19 | 920 | -23 | 143 | 0 |
| 30 Sep 19 | 903 | -11 | 138 | 0 |
| 30 Jun 19 | 1,085 | 27 | 137 | 0 |
| 31 Mar 19 | 1,100 | 33 | 146 | 0 |
| 31 Dec 18 | 1,122 | 26 | 136 | 0 |
| 30 Sep 18 | 1,140 | 29 | 133 | 0 |
| 30 Jun 18 | 1,002 | 2 | 122 | 0 |
| 31 Mar 18 | 1,064 | 11 | 119 | 0 |
| 31 Dec 17 | 1,055 | 31 | 111 | 0 |
| 30 Sep 17 | 1,066 | 41 | 106 | 0 |
| 30 Jun 17 | 1,024 | 36 | 102 | 0 |
| 31 Mar 17 | 948 | 37 | 96 | 0 |
| 31 Dec 16 | 924 | 37 | 96 | 0 |
| 30 Sep 16 | 831 | 29 | 90 | 0 |
| 30 Jun 16 | 767 | 33 | 84 | 0 |
| 31 Mar 16 | 712 | 25 | 80 | 0 |
| 31 Dec 15 | 784 | 30 | 114 | 0 |
| 30 Sep 15 | 896 | 38 | 115 | 0 |
| 30 Jun 15 | 978 | 42 | 76 | 0 |
| 31 Mar 15 | 1,030 | 43 | 85 | 0 |
| 31 Dec 14 | 984 | 34 | 117 | 0 |
| 30 Sep 14 | 881 | 24 | 115 | 0 |
| 30 Jun 14 | 778 | 21 | 72 | 0 |
| 31 Mar 14 | 686 | 25 | 108 | 0 |
| 31 Dec 13 | 619 | 31 | 63 | 0 |
양질의 수익: 506128 has high quality earnings.
이익 마진 증가: 506128's current net profit margins (5.4%) are lower than last year (5.6%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 506128's earnings have grown significantly by 55% per year over the past 5 years.
성장 가속화: 506128's earnings growth over the past year (2.6%) is below its 5-year average (55% per year).
수익 대 산업: 506128 earnings growth over the past year (2.6%) did not outperform the Pharmaceuticals industry 19.1%.
자기자본 수익률
높은 ROE: 506128's Return on Equity (14.3%) is considered low.